DK0654264T3 - Anvendelse af venlafaxin eller en aryloxypropanaminforbindelse til fremstilling af et lægemiddel til behandling af urininkontinens - Google Patents

Anvendelse af venlafaxin eller en aryloxypropanaminforbindelse til fremstilling af et lægemiddel til behandling af urininkontinens

Info

Publication number
DK0654264T3
DK0654264T3 DK94308604T DK94308604T DK0654264T3 DK 0654264 T3 DK0654264 T3 DK 0654264T3 DK 94308604 T DK94308604 T DK 94308604T DK 94308604 T DK94308604 T DK 94308604T DK 0654264 T3 DK0654264 T3 DK 0654264T3
Authority
DK
Denmark
Prior art keywords
venlafaxine
urinary incontinence
compound
aryloxypropanamine
medicament
Prior art date
Application number
DK94308604T
Other languages
Danish (da)
English (en)
Inventor
Karl Bruce Thor
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22566762&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0654264(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK0654264T3 publication Critical patent/DK0654264T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • External Artificial Organs (AREA)
DK94308604T 1993-11-24 1994-11-22 Anvendelse af venlafaxin eller en aryloxypropanaminforbindelse til fremstilling af et lægemiddel til behandling af urininkontinens DK0654264T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15812193A 1993-11-24 1993-11-24

Publications (1)

Publication Number Publication Date
DK0654264T3 true DK0654264T3 (da) 2001-07-30

Family

ID=22566762

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94308604T DK0654264T3 (da) 1993-11-24 1994-11-22 Anvendelse af venlafaxin eller en aryloxypropanaminforbindelse til fremstilling af et lægemiddel til behandling af urininkontinens

Country Status (28)

Country Link
US (1) US5744474A (fr)
EP (1) EP0654264B1 (fr)
JP (1) JP3681009B2 (fr)
KR (1) KR100347277B1 (fr)
CN (1) CN1099284C (fr)
AT (1) ATE201594T1 (fr)
AU (1) AU679269B2 (fr)
CA (1) CA2136120C (fr)
CY (2) CY2245B1 (fr)
CZ (1) CZ289069B6 (fr)
DE (2) DE122005000005I2 (fr)
DK (1) DK0654264T3 (fr)
ES (1) ES2157958T3 (fr)
GE (1) GEP20064000B (fr)
GR (1) GR3036446T3 (fr)
HK (1) HK1013799A1 (fr)
HU (1) HU218920B (fr)
IL (1) IL111705A (fr)
LU (1) LU91140I2 (fr)
NL (1) NL300174I2 (fr)
NO (2) NO313535B1 (fr)
PH (1) PH30741A (fr)
PT (1) PT654264E (fr)
RU (1) RU2152786C2 (fr)
SI (1) SI0654264T1 (fr)
TW (1) TW344661B (fr)
UA (1) UA32429C2 (fr)
ZA (1) ZA949190B (fr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506270A (en) * 1995-01-30 1996-04-09 American Home Products Corporation Venlafaxine in the treatment of hypothalamic amenorrhea in non-depressed women
DK0888330T3 (da) * 1996-03-11 2003-09-01 Lilly Co Eli Fremgangsmåder til behandling eller forebyggelse af interstitiel cystitis
PE57198A1 (es) * 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada
US6274171B1 (en) 1996-03-25 2001-08-14 American Home Products Corporation Extended release formulation of venlafaxine hydrochloride
EP1331003B1 (fr) * 1996-03-25 2015-08-26 Wyeth LLC Composition de venlafaxine à libération prolongée
US6150396A (en) * 1997-03-07 2000-11-21 Eli Lilly And Company Methods of treating or preventing interstitial cystitis
WO2000003701A1 (fr) * 1998-07-16 2000-01-27 Massachusetts Institute Of Technology Composition pour le traitement du stress
US6579899B1 (en) 1998-07-16 2003-06-17 Massachusetts Institute Of Technology Composition for treatment of stress
US6770295B1 (en) * 1998-08-27 2004-08-03 Pharmacia Ab Therapeutic formulation for administering tolterodine with controlled release
US6046242A (en) * 1998-11-27 2000-04-04 Basf Aktiengesellschaft Use of aryl-substituted cyclobutylalkylamines for treating urinary incontinence
US6197828B1 (en) * 1998-12-01 2001-03-06 Sepracor, Inc. Derivatives of (+)-venlafaxine and methods of preparing and using the same
US6342533B1 (en) 1998-12-01 2002-01-29 Sepracor, Inc. Derivatives of (−)-venlafaxine and methods of preparing and using the same
HUP0200898A3 (en) * 1999-04-06 2005-09-28 Sepracor Inc Derivatives of venlafaxine and methods of preparing and using the same
PT1459750E (pt) * 1999-07-01 2005-08-31 Pharmacia & Upjohn Co Llc (s,s)- reboxetina para tratar a fibromialgia ou outras perturbacoes somatoformes
US7291646B2 (en) 1999-11-24 2007-11-06 Wyeth Ethers of O-desmethyl venlafaxine
US6572890B2 (en) * 2000-01-13 2003-06-03 Osmotica Corp. Osmotic device containing venlafaxine and an anti-psychotic agent
DE10027290C2 (de) 2000-06-02 2002-07-11 Basf Coatings Ag Pulverklarlackdispersionen (Pulverslurry-Klarlacke) und ihre Verwendung
DE10059412A1 (de) 2000-11-30 2002-06-13 Gruenenthal Gmbh Verwendung von 1-Phenyl-3-dimethylamino-propanverbindungen zur Therapie der Harninkontinenz
EP1864967A1 (fr) * 2001-02-12 2007-12-12 Wyeth Procédé de fabrication d'O-desméthyl-venlafaxine
US6602911B2 (en) * 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
US7030164B2 (en) * 2001-12-05 2006-04-18 Wyeth Crystalline polymorph of venlafaxine hydrochloride and methods for the preparation thereof
UA77234C2 (en) * 2001-12-05 2006-11-15 Wyeth Corp Monohydrate of venlafaxine hydrochloride and methods for its preparation (variants)
GB0202265D0 (en) * 2002-01-31 2002-03-20 Arachnova Therapeutics Ltd New therapeutic use
AR039164A1 (es) * 2002-03-28 2005-02-09 Synthon Bv Sales de venlafaxina de baja solubilidad en agua
WO2003090743A1 (fr) * 2002-04-24 2003-11-06 Cypress Bioscience, Inc. Prevention et traitement de troubles somatiques fonctionnels, y-compris les troubles lies au stress
DE10224107A1 (de) * 2002-05-29 2003-12-11 Gruenenthal Gmbh Kombination ausgewählter Opioide mit anderen Wirkstoffen zur Therapie der Harninkontinenz
AU2003268361A1 (en) * 2002-08-30 2004-03-19 Watson Pharmaceuticals, Inc. Drug delivery system for treating urinary incontinence
GB0221438D0 (en) * 2002-09-16 2002-10-23 Avecia Ltd Processes and compounds
EP1424079A1 (fr) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Combinaison d'un agoniste du beta-3-récepteur et d'un inhibiteur de recaptage de sérotonine et/ou norépinéphrine
US20070077301A1 (en) * 2002-12-23 2007-04-05 Meyer Glenn A Venlafaxine osmotic device formulation
ATE365554T1 (de) * 2003-04-04 2007-07-15 Dynogen Pharmaceuticals Inc Methode zur behandlung von erkrankungen der unteren harnwege
JP4185154B2 (ja) * 2004-04-30 2008-11-26 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 中枢神経系障害治療用の置換モルホリン化合物
EP2400300A1 (fr) 2004-08-25 2011-12-28 Takeda Pharmaceutical Company Limited Procédé de sélection d'agents préventifs/remèdes pour l'incontinence de stress
JP2007523213A (ja) * 2004-12-23 2007-08-16 テバ ファーマシューティカル インダストリーズ リミティド 医薬的に許容できるデュロキセチンの塩及びその中間体の調製方法
WO2006099459A1 (fr) 2005-03-14 2006-09-21 Teva Pharmaceutical Industries Ltd. Procede de preparation du compose optiquement actif (s)-(+)-n,n-dimethyl-3-(1-naphtalenyloxy)-3-(2-thienyl)propanamine
US7842717B2 (en) 2005-09-22 2010-11-30 Teva Pharmaceutical Industries Ltd. DNT-maleate and methods of preparation thereof
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
EP1954669B1 (fr) 2005-12-01 2015-07-08 Auspex Pharmaceuticals, Inc. Phénétylamines substituées à l activité sérotoninergique et/ou norépinephrinergique
WO2007067581A1 (fr) * 2005-12-05 2007-06-14 Teva Pharmaceutical Industries Ltd. 2-(n-methyl-propanamine)-3-(2-naphtol)thiophene, une impurete du duloxetine chlorhydrate
EP1957470A1 (fr) 2005-12-05 2008-08-20 Wyeth Procede pour la synthese selective d'enantiomeres de 1-(2-amino-1-phenyl-ethyl)-cyclohexanols substitues
EP1826204A1 (fr) 2006-02-28 2007-08-29 Laboratorios Del Dr. Esteve, S.A. Procédé pour la préparation des précurseurs de duloxetine
US20080081067A1 (en) * 2006-10-03 2008-04-03 Gupta Manishkumar Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
EP2514740B1 (fr) 2007-03-15 2018-12-19 Auspex Pharmaceuticals, Inc. O-desmethylvenlafaxines deuteres a action sérotoninergique et/ou norepinephrinergique
EP3820563A4 (fr) 2018-07-11 2022-05-04 Dignify Therapeutics, LLC Procédé de traitement d'un dysfonctionnement de vide

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
US4018895A (en) * 1974-01-10 1977-04-19 Eli Lilly And Company Aryloxyphenylpropylamines in treating depression
GR75395B (fr) * 1980-11-14 1984-07-13 Lilly Co Eli
IE56324B1 (en) * 1982-12-13 1991-06-19 American Home Prod Phenethylamine derivatives and intermediates therefor
US4761501A (en) * 1983-10-26 1988-08-02 American Home Products Corporation Substituted phenylacetamides
US4956388A (en) * 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
KR880007433A (ko) * 1986-12-22 1988-08-27 메리 앤 터커 3-아릴옥시-3-치환된 프로판아민
IL85988A (en) * 1987-04-09 1992-08-18 Lilly Co Eli 1-phenyl-3-naphthalenyloxy-propanamines,process for their preparation and pharmaceutical compositions containing them
SE8804003D0 (sv) * 1988-11-04 1988-11-04 Pharmacia Ab Compounds for the treatment of urinary incontinence
US5250571A (en) * 1988-11-14 1993-10-05 Eli Lilly And Company (S)-norfluoxetine in method of inhibiting serotonin uptake
AU642582B2 (en) * 1991-02-25 1993-10-21 Eli Lilly And Company Treatment of lower urinary tract disorders
US5281624A (en) * 1991-09-27 1994-01-25 Eli Lilly And Company N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof
EP0537915B1 (fr) * 1991-09-27 1995-07-12 Eli Lilly And Company N-alkyl-3-phényl-3-(2-alkylthiophénoxy)propyl amines comme inhibiteurs de norépinéphrine
US5192751A (en) * 1992-07-24 1993-03-09 Eli Lilly And Company Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence

Also Published As

Publication number Publication date
JPH07188003A (ja) 1995-07-25
CY2005002I2 (el) 2010-07-28
ATE201594T1 (de) 2001-06-15
SI0654264T1 (en) 2001-10-31
HK1013799A1 (en) 1999-09-10
LU91140I2 (fr) 2005-04-04
CA2136120C (fr) 2008-01-29
DE69427337T2 (de) 2001-10-31
CN1099284C (zh) 2003-01-22
IL111705A (en) 2001-01-11
EP0654264B1 (fr) 2001-05-30
CZ289069B6 (cs) 2001-10-17
AU7896894A (en) 1995-06-01
CN1107699A (zh) 1995-09-06
KR100347277B1 (ko) 2003-03-06
NL300174I2 (nl) 2005-05-02
PT654264E (pt) 2001-09-28
GR3036446T3 (en) 2001-11-30
CY2005002I1 (el) 2010-07-28
IL111705A0 (en) 1995-01-24
TW344661B (en) 1998-11-11
NO944456D0 (no) 1994-11-21
KR950013511A (ko) 1995-06-15
HU9403369D0 (en) 1995-02-28
DE122005000005I2 (de) 2006-06-08
CZ289394A3 (en) 1995-07-12
PH30741A (en) 1997-10-17
NO313535B1 (no) 2002-10-21
AU679269B2 (en) 1997-06-26
CA2136120A1 (fr) 1995-05-25
EP0654264A1 (fr) 1995-05-24
NO944456L (no) 1995-05-26
ZA949190B (en) 1996-05-20
US5744474A (en) 1998-04-28
RU94041950A (ru) 1996-09-20
RU2152786C2 (ru) 2000-07-20
UA32429C2 (uk) 2000-12-15
CY2245B1 (en) 2003-07-04
DE122005000005I1 (de) 2005-05-12
HU218920B (hu) 2000-12-28
ES2157958T3 (es) 2001-09-01
HUT72317A (en) 1996-04-29
GEP20064000B (en) 2006-12-11
JP3681009B2 (ja) 2005-08-10
NL300174I1 (nl) 2005-04-01
NO2005004I1 (no) 2005-02-10
DE69427337D1 (de) 2001-07-05

Similar Documents

Publication Publication Date Title
DK0654264T3 (da) Anvendelse af venlafaxin eller en aryloxypropanaminforbindelse til fremstilling af et lægemiddel til behandling af urininkontinens
DE122005000002I1 (de) Verwendung von Venlafaxin oder eines Aryloxy-Propanaminderivates zur Herstellung eines Medikaments zur Behandlung von Inkontinenz.
DK0491094T3 (da) Felbamat til behandling af Lennox-Gastaut-syndromet
TW249226B (fr)
DK0532862T3 (da) Anvendelse af rapamycin til fremstilling af et lægemiddel til behandling af øjeninflammation
DK0501705T3 (da) Anvendelse af tomoxetin til behandling af sygdomme i de nedre urinveje
ATE137116T1 (de) Behandlung von entzündlichen erkrankungen mit 15- ketoprostaglandinen
DK0538469T3 (da) Sulfonanilidderivat og lægemiddel
DK0617959T3 (da) Lægemiddel til behandling af hudsygdomme
DK0811376T3 (da) Anvendelse af alkanoyl-L-carnitiner til fremstilling af et lægemiddel til behandling af inflammatoriske tarmsygdomme
WO1991015466A3 (fr) Agents chelateurs
DK0454429T3 (da) Anvendelse af 15-dehydroxy-16-oxoprostaglandinderivater til behandling af allergiske sygdomme
DK453387A (da) Middel til behandling af arteriosklerose og forhindring af blodpladekoagulation
DK0673646T3 (da) Anvendelse af deoxyspergualin til fremstilling af et lægemiddel til behandling af inflammatorisk-hyperreaktive sygdomme
DK0458537T3 (da) Anvendelse af en terapeutisk forbindelse til behandling af bronkitis
ATE72115T1 (de) Anwendung von 1,6-dimethyl-4-oxo-1,6,7,8,9a-
ES2097277T3 (es) Uso de un compuesto ester tiol-s-(2-dietilaminoetilico) para la preparacion de un medicamento para el tratamiento de la incontinencia neuro-muscular.